⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ATOS News
Atossa Therapeutics, Inc. Common Stock
FY 2025 Preliminary and Unaudited Figures Highlighting Significant Progress in the Execution of the Genesis Plan
globenewswire.com
ATOS
SI
Les services publics européens accélèrent leur transformation numérique
businesswire.com
III
ACN
IBM
INFY
DXC
MCHX
ATOS
HIT
WNS
FRST
European Utilities Accelerate Digital Transformation
businesswire.com
III
ACN
CTSH
IBM
INFY
DXC
TTE
NEE
DUK
SO
PCG
EXC
SRE
AEP
CMS
D
WEC
NI
EIX
ETR
FE
XEL
PNW
LNT
ORA
PEG
MGEE
ES
CWEN
AZN
MTCH
GOOG
GOOGL
MSFT
AMZN
ORCL
SAP
CRM
INTC
AMD
NVDA
CSCO
ATOS
EXLS
HIT
WNS
FRST
TECK
Europäische Versorgungsunternehmen beschleunigen die digitale Transformation
businesswire.com
III
ACN
IBM
INFY
DXC
TTEC
ATOS
WNS
FRST
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
prnewswire.com
ATOS
Europäische Unternehmen implementieren beschleunigt und verantwortungsbewusst KI
businesswire.com
III
ACN
ATOS
CGEM
HPE
IBM
INFY
MPW
UIS
DXC
LNG
MATH
SDG
TIGR
VRSN
WNS
TEL
DT
Les entreprises européennes accélèrent l’adoption responsable de l’IA
businesswire.com
III
ACN
ATOS
HPE
IBM
INFY
TDS
DXC
VRSN
European Enterprises Accelerate Responsible AI Adoption
businesswire.com
III
ACN
ATOS
IBM
INFY
TSI
UIS
DXC
MATH
TIGR
VRSN
WNS
Quantum Computing Market Report 2025-2035: Expected to Witness 14.5% CAGR - CNS Disorders Segment to Exhibit Highest Growth Among Therapeutic Areas
globenewswire.com
ACN
AMZN
ATOS
IBM
MSFT
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
prnewswire.com
ATOS